Jim Awad, managing director at Plimsoll Mark Capital, discusses the weaker finish and anemic trading volumes on Wall Street last week.» Read More
The Fast Money traders, along with Paul Forward, Stifel Nicolaus, take a look at the market's decline and what's going on with coal producers, which opened at new, multi-year lows.
Insight on whether this market drop could lead to a correction, with Warren Meyers, DME Securities.
Perspectives on why the markets are lower today and discussing whether a major correction is on the way, with Gordon Charlop, Rosenblatt Securities, and Stephen Guilfoyle, Meridian Equity Partners.
It's fixing to be a busy week in the euro zone, and this strategist wants to steer clear.
So many investors are hunting for yields in the junk bond market, there may not be enough supply to keep up with demand. A strategy for finding opportunities, with Jim Casey, JPMorgan.
A check on the day's market selloff, with John Brady, R.J. O'Brien senior vice president, who says the market is seeing a modest repricing of risk expectations.
Stock prices have doubled over the past three years, but that still hasn't convinced many Americans to invest in the market.
CNBC's Bertha Coombs takes a look at the two percent drop in gold, as metals extend losses on the decreased likelihood of QE3.
U.S. stock index futures fell sharply Tuesday amid renewed concerns that Greece and its private bondholders would not meet the deadline to complete a debt swap and ahead of the Super Tuesday primaries.
Take a look at some of Tuesday morning's early movers:
Insight on the fears overseas that are impacting the market, with Yra Harris, Praxis Trading partner, who says the market will always correct itself and traders are waiting for the jobless numbers this week.
Markets should be poised for a 5 percent correction from their current levels as the global economy remains choked by the ongoing euro zone debt crisis and the rising oil prices pose a threat, a CEO told CNBC Tuesday.
The bulls were all over Keryx Biopharmaceuticals and AEterna Zentaris Monday amid optimism about their Perifosine drug.
Robert Dutkowsky, Tech Data CEO, discusses why his stock was hammered on a revenue miss, and what lies ahead for his company and the entire tech industry, Mad Money's Cramer.
You say the name of a stock, and Mad Money's Jim Cramer tells you whether to buy or sell.
Cramer peeks behind the curtain to find out what's driving Ascena Retail Group's spectacular quarter, and whether investors should buy the stock now or wait for a pullback.
Mad Money's Cramer says DuPont is no longer a stodgy old chemical company with a juicy yield, it's one of the most innovative firms out there, and a pioneer in new technology.
Mad Money host Jim Cramer explains how overblown concerns about China gives the market a chance to work off an overbought and unsustainable rally.
The Fast Money traders share their final trades of the day.
Are ETFs systematically buying most VIX futures and should investors stay away? Matt Hougan, ETF Analytics president, weighs in.